India Raises Cancer Drug Price Caps 50% on Platinum Crunch

Platinum prices have risen roughly 30% over the past year, driven by supply constraints from South Africa and Russia, the two largest producers. The metal is a key raw material in the production of the two drugs. Indian drugmakers had warned the regulator in recent months that the price caps were no longer viable, according to two people familiar with the discussions.

The shortage has been most acute in public hospitals, where patients rely on the government's free drug distribution program. Private hospitals have been able to source limited supplies at higher prices, passing on the increase to patients, doctors said.

The NPPA said it will monitor the supply situation and may adjust the caps again if needed. The regulator also asked state drug controllers to report any continued shortages within two weeks.

For traders watching the commodity side, the link between industrial metal prices and pharmaceutical supply chains is worth noting. Platinum's rally – tied to mine output disruptions in South Africa and export curbs from Russia – has now directly affected drug availability in one of the world's largest generic medicine markets. If platinum stays elevated, the NPPA may face pressure to extend similar relief to other platinum-dependent drugs or revisit the pricing formula itself. The regulator's next review, though unscheduled, will be the key signal on whether this is a one-off fix or the start of a broader adjustment.